Evidence map›Paper›PMID 41488277›Full record

Trial reportFrontiers in aging2025

Trans-resveratrol reduces visible signs of skin ageing in healthy adult females over 40: an 8-week randomized placebo-controlled trial.

Amanda Rao, David Briskey, Georgia Roche, Annie Tremblay, Marcia Da Silva Pinto, Thomas A Tompkins

Abstract readClinical Trial
In one paragraph

Trial report in Frontiers in aging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Amanda RaoRDC Clinical, Brisbane, QLD, Australia.
David BriskeyRDC Clinical, Brisbane, QLD, Australia.
Georgia RocheRDC Clinical, Brisbane, QLD, Australia.
Annie TremblayLallemand Bio-Ingredients, Montreal, QC, Canada.
Marcia Da Silva PintoLallemand Bio-Ingredients, Montreal, QC, Canada.
Thomas A TompkinsLallemand Bio-Ingredients, Montreal, QC, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: This double-blind, randomised, placebo-controlled clinical study evaluated the effects of trans-resveratrol on skin health. To date, and to the best of our knowledge, no study has tested trans-resveratrol as the only active ingredient, orally or topically, for improving skin parameters in humans. Therefore, the aim of this study was to investigate the effects of trans-resveratrol on skin health and visible signs of ageing, when administered orally and/or applied topically to the face. Methods: Healthy females aged 40 years and older were randomly assigned to one of four groups: placebo oral and topical (P/P Group), trans-resveratrol oral and placebo topical (A/P Group), placebo oral and trans-resveratrol topical (P/A Group), and trans-resveratrol oral and topical (A/A Group). Participants were instructed to take one capsule (75 mg trans-resveratrol) and apply 1 g of cream (1.5% trans-resveratrol) twice daily for 8 weeks. Outcome measures included wrinkle assessment, skin age, temperature, pore size, forehead lines, glabellar lines, Crow's feet, nasolabial folds, pigmentation, sebum levels, moisture, and elasticity, along with a self-assessment questionnaire, serum trans-resveratrol concentrations, and safety. Results: Out of 134 participants enrolled, 122 completed the study. Results indicated significantly reduced wrinkle scores in the A/A Group compared to the P/P Group at week 8. All treatment groups showed increased sebum levels, with the active topical groups (P/A and A/A Groups) having significantly higher U-zone sebum at week 8 compared to placebo topical groups (P/P and A/P Groups). No significant differences were found in other skin parameters. Serum trans-resveratrol conjugate levels increased significantly in the A/P and A/A Groups at week 4 and 8. All trial products were shown to be safe with minimal and only mild adverse events recorded in every group. Conclusion: Oral and topical trans-resveratrol treatment can help improve skin health parameters. When taken orally and applied topically, trans-resveratrol was effective at wrinkle reduction, and when applied topically, it increased sebum levels. Clinical Trial Registration: identifier ACTRN12621000709842.

Indexed as

ageingsebumskin healthtrans-resveratrolwrinkles

Identifiers

PMID41488277
PMCPMC12757695

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.